chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 72.0
Sex: F
Vaccine: COVID19, UNK
Symptoms: Abdominal pain upper, Flatulence, Headache, Nausea
Clinical narrative: Nauseous after the 2nd dose; Stomach ache after the 2nd dose; Gassy after the 2nd dose; Headache after the 2nd dose; This spontaneous case was reported by a consumer and describes the occurrence of NAUSEA (Nauseous after the 2nd dose), ABDOMINAL PAIN UPPER (Stomach ache after the 2nd dose), FLATULENCE (Gassy after the 2nd dose) and HEADACHE (Headache after the 2nd dose) in a 72-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 0488b21a) for COVID-19 vaccination.    Co-suspect product included non-company product PARACETAMOL (TYLENOL) for an unknown indication.    No medical history was provided by the reporter.  Concomitant products included Thyroid medication for Thyroid disorder.   On 06-May-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form and PARACETAMOL (TYLENOL) (unknown route) at an unspecified dose. On an unknown date, the patient experienced NAUSEA (Nauseous after the 2nd dose), ABDOMINAL PAIN UPPER (Stomach ache after the 2nd dose), FLATULENCE (Gassy after the 2nd dose) and HEADACHE (Headache after the 2nd dose). At the time of the report, NAUSEA (Nauseous after the 2nd dose), ABDOMINAL PAIN UPPER (Stomach ache after the 2nd dose), FLATULENCE (Gassy after the 2nd dose) and HEADACHE (Headache after the 2nd dose) outcome was unknown. Not Provided      For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.
Age: 60.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Headache, Oropharyngeal pain
Clinical narrative: Sore throat; Fatigue; Headache; This spontaneous case was reported by a consumer and describes the occurrence of OROPHARYNGEAL PAIN (Sore throat), FATIGUE (Fatigue) and HEADACHE (Headache) in a 60-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 05-May-2021, the patient experienced OROPHARYNGEAL PAIN (Sore throat), FATIGUE (Fatigue) and HEADACHE (Headache). At the time of the report, OROPHARYNGEAL PAIN (Sore throat), FATIGUE (Fatigue) and HEADACHE (Headache) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No Concomitant medication were reported.  No treatment medication were reported.
Age: 57.0
Sex: F
Vaccine: COVID19
Symptoms: Chest discomfort, Headache, Injection site pain, Myalgia
Clinical narrative: pressure on the left side of her chest; sore muscles; headache; injection site pain with first dose; body aches; This spontaneous case was reported by a pharmacist and describes the occurrence of CHEST DISCOMFORT (pressure on the left side of her chest), MYALGIA (sore muscles), HEADACHE (headache), INJECTION SITE PAIN (injection site pain with first dose) and MYALGIA (body aches) in a 57-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 025B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 07-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 07-Apr-2021, the patient experienced CHEST DISCOMFORT (pressure on the left side of her chest), MYALGIA (sore muscles), HEADACHE (headache), INJECTION SITE PAIN (injection site pain with first dose) and MYALGIA (body aches). The patient was treated with PARACETAMOL (TYLENOL) at an unspecified dose and frequency. At the time of the report, CHEST DISCOMFORT (pressure on the left side of her chest), MYALGIA (sore muscles), HEADACHE (headache), INJECTION SITE PAIN (injection site pain with first dose) and MYALGIA (body aches) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medication was reported.   This case was linked to MOD-2021-114316 (Patient Link).
Age: 53.0
Sex: F
Vaccine: COVID19
Symptoms: Vertigo
Clinical narrative: Vertigo; This spontaneous case was reported by a consumer and describes the occurrence of VERTIGO (Vertigo) in a 53-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 042B21A) for COVID-19 vaccination.     The patient's past medical history included No adverse reaction.    On 16-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 17-Apr-2021, the patient experienced VERTIGO (Vertigo). At the time of the report, VERTIGO (Vertigo) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.
Age: 84.0
Sex: F
Vaccine: COVID19
Symptoms: Abdominal discomfort, Arthralgia, Cystitis, Ear pain, Herpes zoster
Clinical narrative: outside dosing window; possibility of shingles; bladder infection; swollen armpit; sore throat; stomach discomfort; ear pain; jaw pain; shoulder pain; This spontaneous case was reported by a consumer and describes the occurrence of ARTHRALGIA (shoulder pain), OROPHARYNGEAL PAIN (sore throat), ABDOMINAL DISCOMFORT (stomach discomfort), EAR PAIN (ear pain) and PAIN IN JAW (jaw pain) in an 84-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 30-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 30-Mar-2021, the patient experienced ARTHRALGIA (shoulder pain), EAR PAIN (ear pain) and PAIN IN JAW (jaw pain). On 01-Apr-2021, the patient experienced OROPHARYNGEAL PAIN (sore throat), ABDOMINAL DISCOMFORT (stomach discomfort) and SWELLING (swollen armpit). On 20-Apr-2021, the patient experienced CYSTITIS (bladder infection). On 27-Apr-2021, the patient experienced HERPES ZOSTER (possibility of shingles). On an unknown date, the patient experienced PRODUCT DOSE OMISSION ISSUE (outside dosing window). On 03-Apr-2021, ARTHRALGIA (shoulder pain), OROPHARYNGEAL PAIN (sore throat), ABDOMINAL DISCOMFORT (stomach discomfort), EAR PAIN (ear pain), PAIN IN JAW (jaw pain) and SWELLING (swollen armpit) had resolved. On 04-May-2021, CYSTITIS (bladder infection) and HERPES ZOSTER (possibility of shingles) had resolved. At the time of the report, PRODUCT DOSE OMISSION ISSUE (outside dosing window) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   This case was linked to MOD-2021-114336 (Patient Link).
Age: 84.0
Sex: F
Vaccine: COVID19
Symptoms: Oropharyngeal pain, Pain in jaw, Product dose omission issue, Swelling
Clinical narrative: outside dosing window; possibility of shingles; bladder infection; swollen armpit; sore throat; stomach discomfort; ear pain; jaw pain; shoulder pain; This spontaneous case was reported by a consumer and describes the occurrence of ARTHRALGIA (shoulder pain), OROPHARYNGEAL PAIN (sore throat), ABDOMINAL DISCOMFORT (stomach discomfort), EAR PAIN (ear pain) and PAIN IN JAW (jaw pain) in an 84-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 30-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 30-Mar-2021, the patient experienced ARTHRALGIA (shoulder pain), EAR PAIN (ear pain) and PAIN IN JAW (jaw pain). On 01-Apr-2021, the patient experienced OROPHARYNGEAL PAIN (sore throat), ABDOMINAL DISCOMFORT (stomach discomfort) and SWELLING (swollen armpit). On 20-Apr-2021, the patient experienced CYSTITIS (bladder infection). On 27-Apr-2021, the patient experienced HERPES ZOSTER (possibility of shingles). On an unknown date, the patient experienced PRODUCT DOSE OMISSION ISSUE (outside dosing window). On 03-Apr-2021, ARTHRALGIA (shoulder pain), OROPHARYNGEAL PAIN (sore throat), ABDOMINAL DISCOMFORT (stomach discomfort), EAR PAIN (ear pain), PAIN IN JAW (jaw pain) and SWELLING (swollen armpit) had resolved. On 04-May-2021, CYSTITIS (bladder infection) and HERPES ZOSTER (possibility of shingles) had resolved. At the time of the report, PRODUCT DOSE OMISSION ISSUE (outside dosing window) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   This case was linked to MOD-2021-114336 (Patient Link).
Age: 66.0
Sex: F
Vaccine: COVID19
Symptoms: Product dose omission issue
Clinical narrative: 2nd dose delayed beyond 42 days; This spontaneous case was reported by a pharmacist and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (2nd dose delayed beyond 42 days) in a 66-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PRODUCT DOSE OMISSION ISSUE (2nd dose delayed beyond 42 days). At the time of the report, PRODUCT DOSE OMISSION ISSUE (2nd dose delayed beyond 42 days) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications reported by investigator  No treatment medications provided by the reporter.
Sex: F
Vaccine: COVID19
Symptoms: Urinary tract infection
Clinical narrative: UTI; This spontaneous case was reported by a consumer and describes the occurrence of URINARY TRACT INFECTION (UTI) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced URINARY TRACT INFECTION (UTI). At the time of the report, URINARY TRACT INFECTION (UTI) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant medications details were not reported by the reporter. Treatment included Antibiotics.
Age: 38.0
Sex: F
Vaccine: COVID19
Symptoms: Inappropriate schedule of product administration
Clinical narrative: early second dose; supposed to be on May 21; local health department who okayed her getting the second dose early because she was leaving; This spontaneous case was reported by an other health care professional and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (early second dose), INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (supposed to be on May 21) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (local health department who okayed her getting the second dose early because she was leaving) in a 38-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 014C21A) for COVID-19 vaccination.     No Medical History information was reported.   On 07-May-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 07-May-2021, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (early second dose), INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (supposed to be on May 21) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (local health department who okayed her getting the second dose early because she was leaving). At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (early second dose), INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (supposed to be on May 21) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (local health department who okayed her getting the second dose early because she was leaving) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications reported. No treatment information provided. Action taken with mRNA-123 is not applicable.
Age: 66.0
Sex: F
Vaccine: COVID19
Symptoms: Product dose omission issue
Clinical narrative: This spontaneous case was reported by a pharmacist and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (Second shot is past 42 days from first dose) in a 66-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 012M20A) for COVID-19 vaccination.Concurrent medical conditions included Hypertension and Type 2 diabetes mellitus. Concomitant products included METFORMIN for Diabetes, AMLODIPINE for Hypertension, DL- LACTIC ACID (EUCERIN [DL- LACTIC ACID]) and ATORVASTATIN for an unknown indication. On 25-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PRODUCT DOSE OMISSION ISSUE (Second shot is past 42 days from first dose). At the time of the report, PRODUCT DOSE OMISSION ISSUE (Second shot is past 42 days from first dose) had resolved. Not Provided. The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments. Treatment information was not provided. This case was linked to MOD-2021-216599 (Patient Link). Most recent FOLLOW-UP information incorporated above includes: On 11-Jun-2021: Patient's demographic details, Patient's historical condition, concomitant products Metformin and Amlodipine details were added.
Age: 57.0
Sex: F
Vaccine: COVID19
Symptoms: Bedridden, Eye swelling, Myalgia, Pyrexia, Swelling face
Clinical narrative: face is swollen; eye is swollen underneath; has been in bed for 2 days; fever of 102F; bad body aches/she has really bad myalgia; This spontaneous case was reported by a pharmacist and describes the occurrence of SWELLING FACE (face is swollen), EYE SWELLING (eye is swollen underneath), BEDRIDDEN (has been in bed for 2 days), PYREXIA (fever of 102F) and MYALGIA (bad body aches/she has really bad myalgia) in a 57-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 006C21A and 025B21A) for COVID-19 vaccination.     No Medical History information was reported.   On 07-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 06-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 06-May-2021, the patient experienced SWELLING FACE (face is swollen), EYE SWELLING (eye is swollen underneath), BEDRIDDEN (has been in bed for 2 days), PYREXIA (fever of 102F) and MYALGIA (bad body aches/she has really bad myalgia). The patient was treated with PARACETAMOL (TYLENOL) at an unspecified dose and frequency. At the time of the report, SWELLING FACE (face is swollen), EYE SWELLING (eye is swollen underneath), BEDRIDDEN (has been in bed for 2 days), PYREXIA (fever of 102F) and MYALGIA (bad body aches/she has really bad myalgia) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication was provided.   This case was linked to MOD-2021-114305 (Patient Link).
Age: 53.0
Sex: U
Vaccine: COVID19
Symptoms: Rash
Clinical narrative: Rash under both arms and the end seems of his legs/ Rash is still ongoing; This spontaneous case was reported by a consumer and describes the occurrence of RASH (Rash under both arms and the end seems of his legs/ Rash is still ongoing) in a 53-year-old patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 038B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 23-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced RASH (Rash under both arms and the end seems of his legs/ Rash is still ongoing). At the time of the report, RASH (Rash under both arms and the end seems of his legs/ Rash is still ongoing) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medication details was reported. Treatment medication included as cortisone cream.
Age: 88.0
Sex: F
Vaccine: COVID19
Symptoms: Body temperature, Pain in extremity, Pruritus, Rash, Rash erythematous
Clinical narrative: itching the same day; rash/ red lines on the inside of her arm that run perpendicular to her arm; Tender; sore arm; Rash; This spontaneous case was reported by a consumer and describes the occurrence of PRURITUS (itching the same day), RASH ERYTHEMATOUS (rash/ red lines on the inside of her arm that run perpendicular to her arm), TENDERNESS (Tender), PAIN IN EXTREMITY (sore arm) and RASH (Rash) in an 88-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 031B21A) for COVID-19 vaccination.     Concurrent medical conditions included Blood pressure high, Acid reflux (esophageal) and Thyroid disorder. Concomitant products included LANSOPRAZOLE (PREVACID) for Acid reflux (esophageal), LOSARTAN POTASSIUM (LOSARTIN) and HYDROCHLOROTHIAZIDE, TRIAMTERENE (TRIAMTERENE HCTZ) for Blood pressure high, LEVOTHYROXINE for Thyroid disorder.    On 06-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 06-May-2021, the patient experienced PRURITUS (itching the same day), RASH ERYTHEMATOUS (rash/ red lines on the inside of her arm that run perpendicular to her arm), TENDERNESS (Tender), PAIN IN EXTREMITY (sore arm) and RASH (Rash). On 29-May-2021, PRURITUS (itching the same day), RASH ERYTHEMATOUS (rash/ red lines on the inside of her arm that run perpendicular to her arm), TENDERNESS (Tender), PAIN IN EXTREMITY (sore arm) and RASH (Rash) had resolved. Not Provided    DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 07-May-2021, Body temperature: 97.3 (normal) 97.3 F.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Treatment medication include Anti itch cream.   Most recent FOLLOW-UP information incorporated above includes: On 08-Jun-2021: Reporter's address and email address, Patient's demographic details, Patient's other relevant history, Lab data, Concomitant medications, 2nd dose start date, New event rash with outcome of all events, Causality of events were added.
Age: 88.0
Sex: F
Vaccine: COVID19
Symptoms: Tenderness
Clinical narrative: itching the same day; rash/ red lines on the inside of her arm that run perpendicular to her arm; Tender; sore arm; Rash; This spontaneous case was reported by a consumer and describes the occurrence of PRURITUS (itching the same day), RASH ERYTHEMATOUS (rash/ red lines on the inside of her arm that run perpendicular to her arm), TENDERNESS (Tender), PAIN IN EXTREMITY (sore arm) and RASH (Rash) in an 88-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 031B21A) for COVID-19 vaccination.     Concurrent medical conditions included Blood pressure high, Acid reflux (esophageal) and Thyroid disorder. Concomitant products included LANSOPRAZOLE (PREVACID) for Acid reflux (esophageal), LOSARTAN POTASSIUM (LOSARTIN) and HYDROCHLOROTHIAZIDE, TRIAMTERENE (TRIAMTERENE HCTZ) for Blood pressure high, LEVOTHYROXINE for Thyroid disorder.    On 06-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 06-May-2021, the patient experienced PRURITUS (itching the same day), RASH ERYTHEMATOUS (rash/ red lines on the inside of her arm that run perpendicular to her arm), TENDERNESS (Tender), PAIN IN EXTREMITY (sore arm) and RASH (Rash). On 29-May-2021, PRURITUS (itching the same day), RASH ERYTHEMATOUS (rash/ red lines on the inside of her arm that run perpendicular to her arm), TENDERNESS (Tender), PAIN IN EXTREMITY (sore arm) and RASH (Rash) had resolved. Not Provided    DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 07-May-2021, Body temperature: 97.3 (normal) 97.3 F.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Treatment medication include Anti itch cream.   Most recent FOLLOW-UP information incorporated above includes: On 08-Jun-2021: Reporter's address and email address, Patient's demographic details, Patient's other relevant history, Lab data, Concomitant medications, 2nd dose start date, New event rash with outcome of all events, Causality of events were added.
Sex: F
Vaccine: COVID19
Symptoms: Product dose omission issue
Clinical narrative: It has been 37 days from 1st dose; This spontaneous case was reported by a consumer and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (It has been 37 days from 1st dose) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 01-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 01-Apr-2021, the patient experienced PRODUCT DOSE OMISSION ISSUE (It has been 37 days from 1st dose). At the time of the report, PRODUCT DOSE OMISSION ISSUE (It has been 37 days from 1st dose) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.
Age: 17.0
Sex: F
Vaccine: COVID19
Symptoms: Product administered to patient of inappropriate age
Clinical narrative: patient who is 17 years old and in a similar boat; This spontaneous case was reported by a pharmacist and describes the occurrence of PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (patient who is 17 years old and in a similar boat) in a 17-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 025B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 25-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 25-Apr-2021, the patient experienced PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (patient who is 17 years old and in a similar boat). At the time of the report, PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (patient who is 17 years old and in a similar boat) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant information were not reported. Treatment information were not reported.   This case was linked to MOD-2021-114524 (E2B Linked Report).; Sender's Comments:  MOD-2021-114524:
Age: 78.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Gait disturbance, Pain in extremity, Peripheral swelling
Clinical narrative: Pain in right Hip to knee; Cannot walk; Left arm  swollen; Left arm sore and hurting; This spontaneous case was reported by a consumer and describes the occurrence of PERIPHERAL SWELLING (Left arm  swollen), PAIN IN EXTREMITY (Left arm sore and hurting), ARTHRALGIA (Pain in right Hip to knee) and GAIT DISTURBANCE (Cannot walk) in a 78-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 031A21A) for COVID-19 vaccination.     No Medical History information was reported.    On 23-Apr-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 23-Apr-2021, the patient experienced PERIPHERAL SWELLING (Left arm  swollen) and PAIN IN EXTREMITY (Left arm sore and hurting). On an unknown date, the patient experienced ARTHRALGIA (Pain in right Hip to knee) and GAIT DISTURBANCE (Cannot walk). At the time of the report, PERIPHERAL SWELLING (Left arm  swollen), PAIN IN EXTREMITY (Left arm sore and hurting), ARTHRALGIA (Pain in right Hip to knee) and GAIT DISTURBANCE (Cannot walk) outcome was unknown. Not Provided          No concomitant medication reported. No treatment information provided.   This case was linked to US-MODERNATX, INC.-MOD-2021-114436 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2021-114436:Husband Case
Age: 81.0
Sex: F
Vaccine: COVID19
Symptoms: Asthenia, Chills, Pyrexia
Clinical narrative: Weakness; CHILLS; Fever; This spontaneous case was reported by a consumer and describes the occurrence of ASTHENIA (Weakness), CHILLS (CHILLS) and PYREXIA (Fever) in an 81-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 018B21A and 011A21A) for COVID-19 vaccination.     Concurrent medical conditions included Blood pressure high, Asthma (Intermittent asthma), Allergic rhinitis, UTI (Patient has history of frequent UTIs) and Migraine (Patient states that they have frequent migraines at baseline.). Concomitant products included TELMISARTAN and HCTZ for Blood pressure management, GABAPENTIN for Headache, ALLOPURINOL, MONTELUKAST, PANTOPRAZOLE and POTASSIUM for an unknown indication.   On 03-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 07-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 08-Apr-2021, the patient experienced ASTHENIA (Weakness), CHILLS (CHILLS) and PYREXIA (Fever). The patient was treated with BUTALBITAL, PARACETAMOL (BUTALBITAL AND ACETAMINOPHEN) at an unspecified dose and frequency and PARACETAMOL (TYLENOL) at an unspecified dose and frequency. On 09-Apr-2021, ASTHENIA (Weakness), CHILLS (CHILLS) and PYREXIA (Fever) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Treatment medication also included two antibiotics  The patient reported a weeklong after the second immunization then sporadic, weakness in body, the shot might be exacerbated that, fever, and chills.   This case was linked to MOD-2021-114295 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 23-Jul-2021: Follow-up was received. Updated patient demographics. Added Medical history. Added additional concomitant medications.
Age: 23.0
Sex: F
Vaccine: COVID19
Symptoms: Rash
Clinical narrative: Rash; This spontaneous case was reported by a non-health professional and describes the occurrence of RASH (Rash) in a 23-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 05-May-2021, the patient experienced RASH (Rash). At the time of the report, RASH (Rash) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.
Age: 55.0
Sex: F
Vaccine: COVID19
Symptoms: Product dose omission issue, Urticaria
Clinical narrative: the clinic did not administer the second COVID vaccine; hives; This spontaneous case was reported by a nurse and describes the occurrence of URTICARIA (hives) and PRODUCT DOSE OMISSION ISSUE (the clinic did not administer the second COVID vaccine) in a 55-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 029A21A) for COVID-19 vaccination.     No Medical History information was reported.    On 12-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 12-Mar-2021, the patient experienced URTICARIA (hives). On an unknown date, the patient experienced PRODUCT DOSE OMISSION ISSUE (the clinic did not administer the second COVID vaccine). On 13-Mar-2021, URTICARIA (hives) had resolved. At the time of the report, PRODUCT DOSE OMISSION ISSUE (the clinic did not administer the second COVID vaccine) had resolved. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant drugs are not provided. Treatment information does not provided.   Most recent FOLLOW-UP information incorporated above includes: On 08-Jun-2021: Added event information
Age: 21.0
Sex: M
Vaccine: COVID19
Symptoms: Arthralgia, Headache
Clinical narrative: Sore arm pain spanning for two days; consist headaches; This spontaneous case was reported by a consumer and describes the occurrence of ARTHRALGIA (Sore arm pain spanning for two days) and HEADACHE (consist headaches) in a 21-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 002C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 23-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 23-Apr-2021, the patient experienced HEADACHE (consist headaches). On an unknown date, the patient experienced ARTHRALGIA (Sore arm pain spanning for two days). The patient was treated with ACETAMINOPHEN for Symptomatic treatment, at an unspecified dose and frequency. At the time of the report, ARTHRALGIA (Sore arm pain spanning for two days) and HEADACHE (consist headaches) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant medications were not provided.
Age: 66.0
Sex: M
Vaccine: COVID19
Symptoms: Pruritus, Rash
Clinical narrative: little bit itchy; whole body rash; This spontaneous case was reported by a consumer and describes the occurrence of PRURITUS (little bit itchy) and RASH (whole body rash) in a 66-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 018B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 25-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 15-Apr-2021, the patient experienced PRURITUS (little bit itchy) and RASH (whole body rash). The patient was treated with LORATADINE (CLARITIN [LORATADINE]) at an unspecified dose and frequency. At the time of the report, PRURITUS (little bit itchy) and RASH (whole body rash) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   No concomitant medications were provided.  Patient did not have any reactions after the second shot.
Age: 64.0
Sex: F
Vaccine: COVID19
Symptoms: Blood pressure measurement, Cough, Headache
Clinical narrative: Blood Pressure; Cough; Horrible headache; This spontaneous case was reported by a consumer and describes the occurrence of COUGH (Cough), HEADACHE (Horrible headache) and BLOOD PRESSURE MEASUREMENT (Blood Pressure) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 016C21A) for COVID-19 vaccination.     No medical history was provided by the reporter.  Concomitant products included Protentil as needed for an unknown indication.    On 04-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 04-May-2021, the patient experienced COUGH (Cough) and HEADACHE (Horrible headache). On 06-May-2021, the patient experienced BLOOD PRESSURE MEASUREMENT (Blood Pressure). At the time of the report, COUGH (Cough) and HEADACHE (Horrible headache) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Treatment information provided was Tylenol and Benadryl.
Age: 16.0
Sex: M
Vaccine: COVID19
Symptoms: Product administered to patient of inappropriate age
Clinical narrative: Administered vaccine to patient below recommended age population (under 18 years of age old); This spontaneous case was reported by a consumer and describes the occurrence of PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (Administered vaccine to patient below recommended age population (under 18 years of age old)) in a 16-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 06-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 06-Apr-2021, the patient experienced PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (Administered vaccine to patient below recommended age population (under 18 years of age old)). At the time of the report, PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (Administered vaccine to patient below recommended age population (under 18 years of age old)) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medication was reported.
Age: 44.0
Sex: F
Vaccine: COVID19
Symptoms: Abdominal pain upper, Anxiety, Chills, Fatigue, Influenza like illness
Clinical narrative: Flu like symptoms; it was hard to keep stuff down; heightened anxiety; stomachache; vomiting; exhausted; running a fever; chills; This spontaneous case was reported by a consumer and describes the occurrence of INFLUENZA LIKE ILLNESS (Flu like symptoms), MOBILITY DECREASED (it was hard to keep stuff down), ANXIETY (heightened anxiety), ABDOMINAL PAIN UPPER (stomachache) and VOMITING (vomiting) in a 44-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 03TBZ1A and 04B21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included Post-traumatic stress disorder, Anxiety, Concussion (4 concussions), Traumatic brain injury and Memory disturbance. Concomitant products included ATENOLOL for Palpitations, SERTRALINE for Post-traumatic stress disorder, TRAZODONE for Sleep disorder, PRAZOSIN and VITAMIN D NOS for an unknown indication.   On 13-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 09-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 13-Apr-2021, the patient experienced INFLUENZA LIKE ILLNESS (Flu like symptoms), MOBILITY DECREASED (it was hard to keep stuff down), ANXIETY (heightened anxiety), ABDOMINAL PAIN UPPER (stomachache), VOMITING (vomiting), FATIGUE (exhausted), PYREXIA (running a fever) and CHILLS (chills). On 16-Apr-2021, ANXIETY (heightened anxiety), ABDOMINAL PAIN UPPER (stomachache), PYREXIA (running a fever) and CHILLS (chills) had resolved. At the time of the report, INFLUENZA LIKE ILLNESS (Flu like symptoms), MOBILITY DECREASED (it was hard to keep stuff down), VOMITING (vomiting) and FATIGUE (exhausted) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Treatment for the events were not provided.The patient was expected to receive second dose after 25 days on MAY 09,2021 the vaccination facility refuses to provide her the second dose today as it is 2 days early. Past medical history included hit and runs too. .Patient blood pressure normally runs a little low and the medications were not used for the blood pressure maintenance.   Most recent FOLLOW-UP information incorporated above includes: On 13-May-2021: Second dose details were provided
Age: 44.0
Sex: F
Vaccine: COVID19
Symptoms: Mobility decreased, Pyrexia, Vomiting
Clinical narrative: Flu like symptoms; it was hard to keep stuff down; heightened anxiety; stomachache; vomiting; exhausted; running a fever; chills; This spontaneous case was reported by a consumer and describes the occurrence of INFLUENZA LIKE ILLNESS (Flu like symptoms), MOBILITY DECREASED (it was hard to keep stuff down), ANXIETY (heightened anxiety), ABDOMINAL PAIN UPPER (stomachache) and VOMITING (vomiting) in a 44-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 03TBZ1A and 04B21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included Post-traumatic stress disorder, Anxiety, Concussion (4 concussions), Traumatic brain injury and Memory disturbance. Concomitant products included ATENOLOL for Palpitations, SERTRALINE for Post-traumatic stress disorder, TRAZODONE for Sleep disorder, PRAZOSIN and VITAMIN D NOS for an unknown indication.   On 13-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 09-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 13-Apr-2021, the patient experienced INFLUENZA LIKE ILLNESS (Flu like symptoms), MOBILITY DECREASED (it was hard to keep stuff down), ANXIETY (heightened anxiety), ABDOMINAL PAIN UPPER (stomachache), VOMITING (vomiting), FATIGUE (exhausted), PYREXIA (running a fever) and CHILLS (chills). On 16-Apr-2021, ANXIETY (heightened anxiety), ABDOMINAL PAIN UPPER (stomachache), PYREXIA (running a fever) and CHILLS (chills) had resolved. At the time of the report, INFLUENZA LIKE ILLNESS (Flu like symptoms), MOBILITY DECREASED (it was hard to keep stuff down), VOMITING (vomiting) and FATIGUE (exhausted) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Treatment for the events were not provided.The patient was expected to receive second dose after 25 days on MAY 09,2021 the vaccination facility refuses to provide her the second dose today as it is 2 days early. Past medical history included hit and runs too. .Patient blood pressure normally runs a little low and the medications were not used for the blood pressure maintenance.   Most recent FOLLOW-UP information incorporated above includes: On 13-May-2021: Second dose details were provided
Age: 84.0
Sex: F
Vaccine: COVID19
Symptoms: Product administration interrupted
Clinical narrative: was due for the 2nd dose on 27Apr2021; This spontaneous case was reported by a consumer and describes the occurrence of PRODUCT ADMINISTRATION INTERRUPTED (was due for the 2nd dose on 27Apr2021) in an 84-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Drug hypersensitivity (Allergic to Thimerosal), Drug hypersensitivity (Allergic to Neosporin), Drug hypersensitivity (Allergic to Bacitracin.), Drug hypersensitivity (Allergic to Neomycin) and Allergy (Allergic to things used in Lubricants and Shampoos.).    On 30-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PRODUCT ADMINISTRATION INTERRUPTED (was due for the 2nd dose on 27Apr2021). At the time of the report, PRODUCT ADMINISTRATION INTERRUPTED (was due for the 2nd dose on 27Apr2021) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications were reported. The patient reported of shringles and bladder infection but wasn't sure if the patient had them or not. The treatment medications included Cephalexin from 28 APR 2021 to 27Apr2021 for Shringles, Vancyclovir 27Apr2021 to 4May2021 for Bladder infection and Prednisone 27Apr2021 to 4May2021   This case was linked to MOD-2021-114310 (Patient Link).
Age: 31.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site pain
Clinical narrative: pain in the arm of injection; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PAIN (pain in the arm of injection) in a 31-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 010M20A) for COVID-19 vaccination.     No medical history information was reported.  Concomitant products included VITAMIN C [ASCORBIC ACID] for an unknown indication.    On 11-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VACCINATION SITE PAIN (pain in the arm of injection). The patient was treated with IBUPROFEN for Adverse event, at an unspecified dose and frequency. At the time of the report, VACCINATION SITE PAIN (pain in the arm of injection) outcome was unknown. Not Provided      mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) dosing remained unchanged.       Concomitant medications also included 'Woman Vitamin' for nails.   This case was linked to MOD-2021-114356 (Patient Link).
Age: 80.0
Sex: F
Vaccine: COVID19
Symptoms: Product dose omission issue
Clinical narrative: Patient did not receive the second dose within the appropriate window of time between two doses; This spontaneous case was reported by a pharmacist and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (Patient did not receive the second dose within the appropriate window of time between two doses) in an 80-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 031M20A) for COVID-19 vaccination.     No Medical History information was reported.    On 01-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 01-Feb-2021, the patient experienced PRODUCT DOSE OMISSION ISSUE (Patient did not receive the second dose within the appropriate window of time between two doses). At the time of the report, PRODUCT DOSE OMISSION ISSUE (Patient did not receive the second dose within the appropriate window of time between two doses) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.
Age: 39.0
Sex: F
Vaccine: COVID19
Symptoms: Body temperature, Myalgia, Pyrexia
Clinical narrative: low grade fever with temperature 100.7F; bad muscle pain; This spontaneous case was reported by a consumer and describes the occurrence of PYREXIA (low grade fever with temperature 100.7F) and MYALGIA (bad muscle pain) in a 39-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 021C21A) for COVID-19 vaccination.     No Medical History information was reported.   On 07-May-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 07-May-2021, the patient experienced PYREXIA (low grade fever with temperature 100.7F) and MYALGIA (bad muscle pain). The patient was treated with PARACETAMOL (TYLENOL) at a dose of 500 milligram. At the time of the report, PYREXIA (low grade fever with temperature 100.7F) and MYALGIA (bad muscle pain) outcome was unknown. Not Provided    DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 07-May-2021, Body temperature: 100.7 (abnormal) 100.7F.   No concomitant medication was provided.
Age: 66.0
Sex: F
Vaccine: COVID19
Symptoms: Burning sensation, Cough, Pruritus, Rash, Seasonal allergy
Clinical narrative: Coughing; seasonal allergies; she had injection site pain; Rash; she experience a burning; Itchy; This spontaneous case was reported by a consumer and describes the occurrence of BURNING SENSATION (she experience a burning), PRURITUS (Itchy), COUGH (Coughing), SEASONAL ALLERGY (seasonal allergies) and VACCINATION SITE PAIN (she had injection site pain) in a 66-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 28-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 07-Mar-2021, the patient experienced BURNING SENSATION (she experience a burning), PRURITUS (Itchy) and RASH (Rash). On an unknown date, the patient experienced COUGH (Coughing), SEASONAL ALLERGY (seasonal allergies) and VACCINATION SITE PAIN (she had injection site pain). On 07-Mar-2021, BURNING SENSATION (she experience a burning), PRURITUS (Itchy) and RASH (Rash) had resolved. At the time of the report, COUGH (Coughing), SEASONAL ALLERGY (seasonal allergies) and VACCINATION SITE PAIN (she had injection site pain) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.
Age: 66.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site pain
Clinical narrative: Coughing; seasonal allergies; she had injection site pain; Rash; she experience a burning; Itchy; This spontaneous case was reported by a consumer and describes the occurrence of BURNING SENSATION (she experience a burning), PRURITUS (Itchy), COUGH (Coughing), SEASONAL ALLERGY (seasonal allergies) and VACCINATION SITE PAIN (she had injection site pain) in a 66-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 28-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 07-Mar-2021, the patient experienced BURNING SENSATION (she experience a burning), PRURITUS (Itchy) and RASH (Rash). On an unknown date, the patient experienced COUGH (Coughing), SEASONAL ALLERGY (seasonal allergies) and VACCINATION SITE PAIN (she had injection site pain). On 07-Mar-2021, BURNING SENSATION (she experience a burning), PRURITUS (Itchy) and RASH (Rash) had resolved. At the time of the report, COUGH (Coughing), SEASONAL ALLERGY (seasonal allergies) and VACCINATION SITE PAIN (she had injection site pain) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.